Pharma Mar (NASDAQ:PHMMF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Saturday.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Shares of Pharma Mar (NASDAQ:PHMMF) opened at 4.4000 on Friday. The company’s market cap is $1.09 billion. The company has a 50-day moving average price of $4.46 and a 200-day moving average price of $4.01. Pharma Mar has a 12-month low of $2.40 and a 12-month high of $4.80.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Pharma Mar (PHMMF) to Hold” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2017/09/11/zacks-investment-research-downgrades-pharma-mar-phmmf-to-hold.html.
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.